| Literature DB >> 30423393 |
Scott M Grundy, Neil J Stone, Alison L Bailey, Craig Beam, Kim K Birtcher, Roger S Blumenthal, Lynne T Braun, Sarah de Ferranti, Joseph Faiella-Tommasino, Daniel E Forman, Ronald Goldberg, Paul A Heidenreich, Mark A Hlatky, Daniel W Jones, Donald Lloyd-Jones, Nuria Lopez-Pajares, Chiadi E Ndumele, Carl E Orringer, Carmen A Peralta, Joseph J Saseen, Sidney C Smith, Laurence Sperling, Salim S Virani, Joseph Yeboah.
Abstract
Entities:
Keywords: ACC/AHA Clinical Practice Guidelines; Guidelines; LDL-cholesterol; biomarkers; cardiovascular disease; cholesterol; coronary artery calcium score; diabetes mellitus; drug therapy; ezetimibe; hydroxymethylglutaryl-CoA reductase inhibitors/statins; hypercholesterolemia; lipids; patient compliance; pharmacological; primary prevention; proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9) inhibitors; risk assessment; risk reduction discussion; risk treatment discussion; secondary prevention
Mesh：
Substances：
Year: 2018 PMID： 30423393 DOI： 10.1016/j.jacc.2018.11.003
Source DB: PubMed Journal: J Am Coll Cardiol ISSN： 0735-1097 Impact factor: 24.094